By Anirban SenBy Anirban Sen
作者：阿尼爾班·森
New York, Nov 12 (Reuters) - Pfizer Pfe.n Is Exploring the Sale of Its Hospital Drugs Unit, as the Drugmaker, Which Has Been Under Pressure From Activist Investor Starboard Value, Looks to Divest Non-Core Assets, According to Three People Familiar With the Matter.
紐約，11月12日（路透社）——輝瑞 Pfe.n 三位知情人士稱，這家受到激進投資者Starboard Value壓力的製藥商正在探索出售其醫院藥品部門，該公司正尋求剝離非核心資產。
The Unit, Now Called Pfizer Hospital, Was Formed After Pfizer Bought Hospira for About $17 Billion in 2015. the Pharma Giant Has Hired Goldman Sachs to Gauge Initial Interest From Potential Buyers, Which Include Private Equity Firms and Other Pharmaceutical Companies, the Sources Said, Requesting Anonymity as the Discussions Are Confidential.
該單位現名爲輝瑞醫院，是在輝瑞之後成立的 買了 霍斯皮拉在2015年以約170億美元的價格出售。消息人士稱，這家制藥巨頭已聘請高盛來評估包括私募股權公司和其他製藥公司在內的潛在買家的初始利息，並要求匿名，因爲討論是保密的。
After Its Takeover of Hospira, Pfizer Combined the Biosimilars Business With Its Own Unit That Manufactured Lower-Cost Near Copies of Expensive Biotech Drugs. in 2017, Pfizer Sold the Hospital Infusion System Business That It Had Acquired Through the Takeover.
在收購霍斯皮拉後，輝瑞將生物仿製藥業務與自己的部門合併，該部門生產的低成本幾乎是昂貴生物技術藥物的副本。2017年，輝瑞出售了通過收購收購的醫院輸液系統業務。
The Pfizer Hospital Unit Is Now a Subsidiary Focused Primarily on Antibiotics and Other Drugs Delivered as Sterile Infusions or Injectibles in Hospitals and Clinics.
輝瑞醫院部門現在是一家子公司，主要專注於醫院和診所以無菌輸液或注射劑形式交付的抗生素和其他藥物。
The Business, Which Could Be Worth a Few Billion Dollars, Currently Generates Nearly $500 Million of Earnings Before Interest, Taxes, Depreciation and Amortization, the Sources Said, Cautioning That a Deal Is Not Guaranteed and Pfizer Could Choose to Keep the Division.
消息人士稱，該業務可能價值幾十億美元，目前在扣除利息、稅項、折舊和攤銷前創造了近5億美元的收益，並警告說，這筆交易沒有保障，輝瑞可能會選擇保留該部門。
Pfizer and Goldman Declined to Comment.
輝瑞和高盛拒絕置評。
New York-Based Pfizer, Which Held Long-Term Debt of $61.5 Billion at the End of 2023, Has Been Shedding Non-Core Businesses and Ownership Stakes in Companies to Reduce Its Debt Pile. in October, Pfizer Sold a Stake Worth About $3.26 Billion in British Consumer Healthcare Group Haleon Hln.l.
總部位於紐約的輝瑞在2023年底持有615億美元的長期債務，該公司一直在削減公司的非核心業務和所有權以減少其債務堆積。10月，輝瑞公司 出售了股份 英國消費者醫療保健集團Haleon的價值約32.6億美元 hln.l.
The Moves Come at a Time When Pfizer, Led by Chief Executive Albert Bourla, Is Facing Pressure From Starboard, Which Has Criticized Management for Overspending on Big Acquisitions and Failing to Produce Profitable New Drugs From Those Deals or From Its Internal Research and Development.
這些舉措是在首席執行官阿爾伯特·布爾拉領導的輝瑞面臨的時候採取的 來自右舷的壓力，它批評管理層在重大收購上超支，未能通過這些交易或內部研發生產出有利可圖的新藥。
Last Year, It Acquired Cancer Drugmaker Seagen for $43 Billion in What Was One of the Company's Biggest Ever Deals.
去年，它收購了 癌症製藥商西根 以430億美元的價格出售，這是該公司有史以來最大的交易之一。
Pfizer's Shares Are Down About 7% This Year, Underperforming the S&P 500 .spx, Which Has Risen Nearly 26% During the Same Period.
輝瑞股價今年下跌約7％，表現低於標準普爾500指數 .spx，同期上漲了近26％。
On Its Most Recent Post-Earnings Conference Call, Pfizer CFO Dave Denton Said the Company Has Paid Down About $4.4 Billion of Debt This Year and Would Continue to Evaluate Non-Core Assets That Could Be Offloaded.
輝瑞首席財務官戴夫·丹頓在最近的業績後電話會議上表示，該公司今年已經償還了約44億美元的債務，並將繼續評估可能被轉移的非核心資產。
(Reporting by Anirban Sen in New York; Additional Reporting by Michael Erman; Editing by Caroline Humer and Nick Zieminski)
（阿尼爾班·森在紐約的報道；邁克爾·厄爾曼的補充報道；卡羅琳·胡默和尼克·齊明斯基的編輯）
((Anirban.sen@Thomsonreuters.com; Twitter: @Asenjourno; Reuters Messaging: Signal/Telegram/Whatsapp - +1-646-705-9409))
((Anirban.sen@Thomsonreuters.com；推特：@Asenjourno；路透社消息：信號/電報/Whatsapp-+1-646-705-9409))
